BR112012007075A2 - genes, métodos e composições relacionadas á neurogênese e sua modulação - Google Patents

genes, métodos e composições relacionadas á neurogênese e sua modulação

Info

Publication number
BR112012007075A2
BR112012007075A2 BR112012007075A BR112012007075A BR112012007075A2 BR 112012007075 A2 BR112012007075 A2 BR 112012007075A2 BR 112012007075 A BR112012007075 A BR 112012007075A BR 112012007075 A BR112012007075 A BR 112012007075A BR 112012007075 A2 BR112012007075 A2 BR 112012007075A2
Authority
BR
Brazil
Prior art keywords
methods
neurogenesis
pharmaceutical agents
proliferation
genes
Prior art date
Application number
BR112012007075A
Other languages
English (en)
Inventor
Hollis Cline
Timothy Tully
Original Assignee
Dart Neuroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Llc filed Critical Dart Neuroscience Llc
Publication of BR112012007075A2 publication Critical patent/BR112012007075A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

genes, métodos e composições relacionadas á neurogênese e sua modulação. a presente divulgação fornece métodos para investigar a neurogênese, proliferação e diferenciação de células neurais. especificamente, a presente divulgação diz respeito a métodos para a identificação de agentes farmacêuticos capazes de modular a neurogênese e proliferação de células neurais, métodos de rastreio para os genes que modulam a neurogênese e proliferação de células progenitoras neurais, e métodos de identificação de agentes farmacêuticos como modulares candidatos da neurogênese e proliferação ou diferenciação neural. a presente divulgação também diz respeito a métodos para a identificação de agentes farmacêuticos para caracterizar e modular neurogênese, agentes farmacêuticos identificados por tais métodos, métodos para o tratamento de pacientes com tais agentes farmacêuticos, e composições que contêm tais agentes farmacêuticos. assim, os presentes métodos permitem elucidar os mecanismos que controlam a neurogênese, o desenvolvimento do cérebro e a função em animais saudáveis e em distúrbios do sistema nervoso. além disso, os presentes métodos facilitam o desenvolvimento de composições para prevenir, melhorar ou estabilizar a neurogênese prejudicada em vários distúrbios do sistema nervoso central, incluindo distúrbios cognitivos.
BR112012007075A 2009-09-29 2010-09-29 genes, métodos e composições relacionadas á neurogênese e sua modulação BR112012007075A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24696709P 2009-09-29 2009-09-29
PCT/US2010/050695 WO2011041393A1 (en) 2009-09-29 2010-09-29 Genes, methods, and compositions related to neurogenesis and its modulation

Publications (1)

Publication Number Publication Date
BR112012007075A2 true BR112012007075A2 (pt) 2016-11-22

Family

ID=43780625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007075A BR112012007075A2 (pt) 2009-09-29 2010-09-29 genes, métodos e composições relacionadas á neurogênese e sua modulação

Country Status (12)

Country Link
US (1) US20110076235A1 (pt)
EP (1) EP2494349A4 (pt)
JP (1) JP5850840B2 (pt)
KR (1) KR20120106721A (pt)
CN (1) CN102859356B (pt)
AU (1) AU2010300713A1 (pt)
BR (1) BR112012007075A2 (pt)
CA (1) CA2776149A1 (pt)
IL (1) IL218955A0 (pt)
MX (1) MX2012003773A (pt)
SG (1) SG10201406116RA (pt)
WO (1) WO2011041393A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077135A1 (en) * 2021-10-29 2023-05-04 Duke University Compositions and systems for rna-programmable cell editing and methods of making and using same
CN114306607A (zh) * 2021-12-31 2022-04-12 中国人民解放军军事科学院军事医学研究院 初级纤毛调控生物节律及其相关应用
CN114652480A (zh) * 2022-03-10 2022-06-24 深圳市眼科医院 热带爪蛙视神经损伤模型构建方法、模型及应用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5849995A (en) * 1993-09-27 1998-12-15 The University Of British Columbia Mouse model for Huntington's Disease and related DNA sequences
US6686198B1 (en) * 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US20040005602A1 (en) * 1997-02-27 2004-01-08 The Trustees Of Columbia University DNA encoding the vertebrate homolog of hedgehog, Vhh-1, expressed by the notocord, and uses thereof
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US20050130922A1 (en) * 1997-06-20 2005-06-16 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
AU5275200A (en) * 1999-05-20 2000-12-12 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
AU2001275185A1 (en) * 2000-06-02 2001-12-17 The Regents Of The University Of California Modulating angiogenesis and neurogenesis with goliath proteins
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
ATE466106T1 (de) * 2003-10-10 2010-05-15 Deutsches Krebsforsch Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
EP1679960B1 (en) * 2003-11-07 2009-05-06 VIB vzw Transgenic amphibian models for lymphatic vessel development
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US20120010103A1 (en) * 2009-03-19 2012-01-12 Braendli Andre W Methods of screening using amphibians

Also Published As

Publication number Publication date
CN102859356B (zh) 2016-01-06
US20110076235A1 (en) 2011-03-31
JP5850840B2 (ja) 2016-02-03
EP2494349A1 (en) 2012-09-05
AU2010300713A1 (en) 2012-04-26
MX2012003773A (es) 2012-11-06
JP2013505738A (ja) 2013-02-21
EP2494349A4 (en) 2013-08-07
CN102859356A (zh) 2013-01-02
CA2776149A1 (en) 2011-04-07
IL218955A0 (en) 2012-06-28
KR20120106721A (ko) 2012-09-26
SG10201406116RA (en) 2014-11-27
WO2011041393A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
Salehinejad et al. Transcranial direct current stimulation in attention-deficit hyperactivity disorder: a meta-analysis of neuropsychological deficits
Funke et al. Modulation of cortical inhibition by rTMS–findings obtained from animal models
Rozeske et al. Prefrontal neuronal circuits of contextual fear conditioning
D’Urso et al. Clinical predictors of acute response to transcranial direct current stimulation (tDCS) in major depression
Kim et al. Lateralization of observational fear learning at the cortical but not thalamic level in mice
Raineki et al. Paradoxical neurobehavioral rescue by memories of early-life abuse: the safety signal value of odors learned during abusive attachment
BR112019006918A2 (pt) proteínas actriib variantes e usos das mesmas
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
Koutsikou et al. Top down control of spinal sensorimotor circuits essential for survival
BR112017004062A2 (pt) sistema e método para identificação de um via neural associada a dor crônica através da estimulação nervosa e monitoramento de ondas cerebrais
GT201100308A (es) Derivados de 1-(piperidin-4-il)-pirazol como moduladores de gpr 119
Jáidar et al. Synchronized activation of striatal direct and indirect pathways underlies the behavior in unilateral dopamine‐depleted mice
Campese et al. Lesions of lateral or central amygdala abolish aversive Pavlovian-to-instrumental transfer in rats
BR112012007075A2 (pt) genes, métodos e composições relacionadas á neurogênese e sua modulação
Banerjee et al. Epigenetic control of neurotransmitter expression in olfactory bulb interneurons
DOP2013000102A (es) Moduladores de gpr 119
BR112015030099A2 (pt) marcador para desordens de esfingomielinase ácida e usos do mesmo
Yang et al. Fascia and primo vascular system
Heuer et al. Dopamine-rich grafts alleviate deficits in contralateral response space induced by extensive dopamine depletion in rats
Bessinis et al. Sex-dependent neurochemical effects of environmental enrichment in the visual system
Consales et al. 50-Hz magnetic field impairs the expression of iron-related genes in the in vitro SOD1G93A model of amyotrophic lateral sclerosis
Rinaldi et al. REAC non-invasive neurobiological stimulation for mitigating the impact of internalizing disorders in autism spectrum disorder
GB201021794D0 (en) Treatment and diagnosis of behavioural disorders
Pinto et al. Striatal integration of inverse dopamine and serotonin signals gates learning
Döbrössy et al. Role of experience, training, and plasticity in the functional efficacy of striatal transplants

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]